The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study

Elliott, Tom; Beca, Sorin; Beharry, Rajendra; Tsoukas, Michael A.; Zarruk, Alexandro; Abitbol, Alexander

doi:10.1177/14791641211021374

Cited by 35 publications

(30 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 However, a recent randomized controlled trial in a similar cohort to the current study reported a comparable within-group HbA1c reduction at 8 months in the CGM group. 11 The current chart review study supports reported findings by studies in flash glucose monitoring with a similar population and methodology from Canada (0.8%) 10 and the USA (0.6%). 9 In 2021, Wright et al reported a 1.1% reduction in type 2 diabetes managed with basal insulin therapy and flash glucose monitoring use.…”

Section: Discussionsupporting

confidence: 87%

“…The unequivocal achievement of the primary end point is supported by the observed HbA1c reduction in the larger meta-analysis cohort and the sensitivity analysis demonstrating consistent HbA1c values, which was also reported separately for the Canada cohort. 10 The observed significant decrease in HbA1c in the USA cohort is supported by an earlier prospective randomized controlled trial in intermittent use of real-time CGM in Clinical care/Education/Nutrition a type 2 diabetes cohort using either basal insulin and/ or antihyperglycemic medications, which demonstrated a 1.2% (within group) HbA1c reduction after 6 months. 7 In this mixed cohort, the majority of these participants were non-insulin users who may show a more pronounced change in HbA1c with CGM.…”

Section: Discussionmentioning

confidence: 70%

“…The methodology and population of the current study are analogous to those described by Elliott et al . 10 The current retrospective non-interventional single-arm chart review study was conducted in diabetes centers in the USA. The clinics each performed a database search for potential medical records to be included in the review.…”

Section: Methodsmentioning

confidence: 99%

“…2 While there is increasing evidence to support CGM use in this population, [3][4][5][6] reported evidence of CGM use to support management of a basal insulin regimen is more limited. [7][8][9][10][11] The aim of this real-world study was to evaluate the impact on HbA1c…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

Carlson

Daniel²,

Desantis

et al. 2022

BMJ Open Diab Res Care

Self Cite

View full text Add to dashboard Cite

IntroductionEvidence supporting use of continuous glucose monitoring in type 2 diabetes treated with basal insulin is unclear. This real-world study aimed to assess the impact on glycated hemoglobin (HbA1c) of flash glucose monitoring use in adults with type 2 diabetes managed with basal insulin.Research design and methodsMedical records were reviewed for adult individuals with type 2 diabetes using basal insulin for ≥1 year with or without additional antihyperglycemic medication, HbA1c 8.0%–12.0% prior to FreeStyle Libre Flash Glucose Monitoring use for ≥90 days and an HbA1c measurement recorded between 90 and 194 days after device use. Exclusion criteria included utilization of bolus insulin. Meta-analysis data are from the current study (USA) and a similar Canadian cohort.ResultsMedical record analysis (n=100) from 8 USA study sites showed significant HbA1c decrease of 1.4%±1.3%, from 9.4%±1.0% at baseline to 8.0%±1.2% after device use, p<0.0001 (mean±SD).Meta-analysis of medical records from USA and Canada sites (n=191) showed HbA1c significantly decreased by 1.1%±0.14% (mean±SE), from baseline 9.2%±1.0% to 8.1%±1.1%, p≤0.0001, with moderate to high heterogeneity between sites (Q=43.9, I2=74.9, p<0.0001) explained by differences in baseline HbA1c between sites.The HbA1c improvement in both groups was observed by age group, body mass index, duration of insulin use and sex at birth.ConclusionsIn a real-world retrospective USA study and a meta-analysis of a larger USA and Canada cohort, HbA1c significantly reduced in basal insulin-treated type 2 diabetes, without bolus insulin initiation and following the commencement of ﬂash glucose monitoring technology.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 70%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

Carlson

Daniel²,

Desantis

et al. 2022

BMJ Open Diab Res Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…A retrospective chart review across 6 diabetes centres in Canada of 91 adults with T2DM on basal-only insulin also showed a −0.8% reduction in HbA1c 3–6 months after starting to use the FreeStyle Libre system. 16 Recently, data have also shown that flash glucose monitoring is associated with reductions in HbA1c in people with T2DM on non-insulin therapies. A prospective study on 48 subjects with T2DM saw a 0.46% reduction in HbA1c after 24 weeks with the FreeStyle Libre system.…”

Section: Resultsmentioning

confidence: 99%

Sensor-Based Technology: Bringing Value to People with Diabetes and the Healthcare System in an Evolving World

Glennie¹,

Berard²,

Levrat-Guillen³

2022

CEOR

View full text Add to dashboard Cite

Purpose Evidence demonstrates that glucose-sensing technologies have enabled effective glycemic control for adults and children with type 1 diabetes (T1DM) or adults with type 2 diabetes (T2DM) on insulin therapy or non-insulin therapy. Here, we report on the wider value of glucose-sensing technology from the perspectives of person living with diabetes (PWD), healthcare providers (HCPs), and healthcare policy stakeholders. Methodology Literature searches were conducted to identify published records and analysis, including across various healthcare organizations and agencies, of the impact of the FreeStyle Libre ® flash glucose monitoring system in diabetes. These findings were combined with the outcomes of three healthcare attitudes surveys among PWD and diabetes healthcare professionals in Canada, including two commissioned for this purpose. Results Clinical trials data and real-world evidence have proven the benefits of the FreeStyle Libre system on limiting hypoglycemia, lowering HbA1c, optimizing metrics of glucose control and reducing hospital admissions. These benefits are accompanied by improvements in patients’ quality of life, work productivity, and savings to the health system. The FreeStyle Libre system has created an opportunity to change the organization and delivery of care, including during COVID-19 restrictions on access to standard care, thus generating system-wide benefits in addition to those accrued by patients and HCPs. Conclusion Evidence-based improvements in glucose control for PWD using flash glucose monitoring are accompanied by increased treatment satisfaction and quality of life. Telemedicine with such remote monitoring systems increases the opportunities for simultaneous review of glucose data with HCPs and shared decision-making, thus encouraging adherence with treatment.

show abstract

The use of technology in type 2 diabetes and prediabetes: a narrative review

Liarakos,

Lim,

Leelarathna

et al. 2024

Diabetologia

View full text Add to dashboard Cite

The increasing incidence of type 2 diabetes, which represents 90% of diabetes cases globally, is a major public health concern. Improved glucose management reduces the risk of vascular complications and mortality; however, only a small proportion of the type 2 diabetes population have blood glucose levels within the recommended treatment targets. In recent years, diabetes technologies have revolutionised the care of people with type 1 diabetes, and it is becoming increasingly evident that people with type 2 diabetes can also benefit from these advances. In this review, we describe the current knowledge regarding the role of technologies for people living with type 2 diabetes and the evidence supporting their use in clinical practice. We conclude that continuous glucose monitoring systems deliver glycaemic benefits for individuals with type 2 diabetes, whether treated with insulin or non-insulin therapy; further data are required to evaluate the role of these systems in those with prediabetes (defined as impaired glucose tolerance and/or impaired fasting glucose and/or HbA1c levels between 39 mmol/mol [5.7%] and 47 mmol/mol [6.4%]). The use of insulin pumps seems to be safe and effective in people with type 2 diabetes, especially in those with an HbA1c significantly above target. Initial results from studies exploring the impact of closed-loop systems in type 2 diabetes are promising. We discuss directions for future research to fully understand the potential benefits of integrating evidence-based technology into care for people living with type 2 diabetes and prediabetes. Graphical Abstract

show abstract

The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study

Cited by 35 publications

References 12 publications

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

Sensor-Based Technology: Bringing Value to People with Diabetes and the Healthcare System in an Evolving World

The use of technology in type 2 diabetes and prediabetes: a narrative review

Contact Info

Product

Resources

About